Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Obrindatamab + Retifanlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Obrindatamab | MGD009|MGD-009|MGD 009 | CD276 Antibody 16 CD3 Antibody 99 | Obrindatamab (MGD009) is an activating bispecific molecule that binds to both B7-H3 (CD276) and CD3, therefore bringing the targeted B7-H3-expressing cells together with T-cells, resulting in cytotoxic immune response (J Clin Oncol., 34 (no. 15_suppl): abstract TPS3105). | |
Retifanlimab | Zynyz | MGA 012|INCMGA00012|MGA012|retifanlimab-dlwr | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Zynyz (retifanlimab) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). Zynyz (retifanlimab) is FDA approved for use in adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03406949 | Phase I | Obrindatamab + Retifanlimab | MGD009/MGA012 Combination in Relapsed/Refractory Cancer | Completed | USA | 0 |